BRAF Biomarkers
News and reporting on BRAF biomarkers.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
The firm's BRAF inhibitor, PLX8394, targets cancers with non-V600 BRAF mutations that see little benefit from BRAF inhibitors currently on the market.
Day One Biopharmaceuticals Raises $130M in Series B Funding
The firm will use the funds to advance its RAF-inhibitor, DAY101, which is being studied in children with BRAF-altered low-grade glioma.
Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC
The study is evaluating the drug in previously treated NSCLC patients with alterations in EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET.
In the study, more than 80 percent of multiple myeloma patients with BRAF V600E mutations saw their tumor shrink after receiving Braftovi and Mektovi.
Sep 23, 2020
Novellus Raises $57M in Series C Funding
Aug 26, 2020